Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.93%
#3 Glidr Glidr +36.87%
#4 MowCat MowCat +27.93%
#5 Humanity Humanity +27.03%
#6 Codatta Codatta +18.91%
#7 Collector Crypt Collector Crypt +18.23%
#8 Walrus Walrus +18.21%
#9 Provenance Blockchain Provenance Blockchain +17.26%
#10 Enso Enso +16.84%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Affimed N.V. Affimed N.V.

Affimed N.V.

AFMD
Classement en actions #36349
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise,... Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.
Prix de l'action
$0.1815
Dernière synchronisation: 2026-04-06
Capitalisation boursière
$2.78M
Changement (1 jour)
0.00%
Changement (1 an)
365.38%
Pays
DE
Échange Affimed N.V. (AFMD)

Catégorie

Healthcare
Historique du prix de l'action pour Affimed N.V. (AFMD)
Prix de clôture le plus élevé : $0.18 le 2026-04-01

Prix de clôture le plus bas : $62.39 le 2014-09-01
Historique du prix de l'action de Affimed N.V. de 2014 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 0.83%
2025 -90.07%
2024 -57.88%
2023 -70.32%
2022 -75.20%
2021 -6.12%
2020 142.60%
2019 -25.12%
2018 134.16%
2017 -23.40%
2016 -73.12%
2015 13.03%
2014 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE